Major Psychedelics VC & EFT Directors Will Share Valuable Insights At Upcoming Benzinga Event

The Benzinga Psychedelics Capital Conference (PCC) is rapidly becoming the place to be for all those interested or involved in the space. In addition to being the place where deals are done, you'll have the opportunity to meet, connect with and learn from some of the most knowledgeable people in the ever-expanding world of psychedelics.

Some of the people you can expect to meet at the Benzinga Psychedelics Capital Conference on April 13th, following our established Cannabis Capital Conference (CCC) at the Fontainebleau Miami Beach Hotel in Florida include world-respected researcher Dr. Matthew Johnson and company leaders such as Najla Guthrie, Joseph Tucker and Kaia Roman. Key advisors including Kevin Harrington, Courtney Barnes, Bryan Passman and David Traylor will also be on hand.

Here’s a quick bio of some of the top VC funds and EFT leaders who will be sharing their ideas at the event. 

Andrew Chomer, Managing Partner at VC Integrated

Andrew Chomer has over 15 years of experience in leading, growing and operating businesses in data, technology and media industries at the global holding company level. 

After focusing on operations, marketing and revenue at innovative healthcare organizations in the senior care and patient experience space Vesta Healthcare (formerly Hometeam) and Pager, Chomer formed Integrated. 

These venture fund partners with value-aligned companies and entrepreneurs are redefining and transforming healthcare and well-being through innovation in digital health initiatives, transformative therapies, consumer wellness brands, food system innovations and mental health initiatives.

Integrated VC is guided by three deeply rooted values: Begin with intention, Live in wonder, and Stay human. Their portfolio comprises drug R&D companies like Amanda Feilding’s Beckley Psytech, Paul Stamets’ MycoMedica, Small Pharma DMTTF, Transcend Therapeutics, as well as ancillary services providers such as Homecoming, Outro Health, Tripp, Wave Neuroscience and WellSet. 

Simeon Schnapper, Founder And Managing Partner at JLS Fund

Schnapper has been involved in psychedelic philanthropy and research for over 30 years. 

A lifelong student and long-time investor in psychedelics with a keen interest in the cultural, regulatory and venture landscapes of the industry, Schnapper advises psychedelic start-ups and is a founding partner at JLS.

Also part of Benzinga’s Psychedelic Advisory Council, Schnapper recently provided some great insights into what is believed to be one of the sector’s verticals: therapists’ training.

JLS is an early-stage plant medicine venture fund investing in the intersection of science, technology and neurology, including early-stage drug development and discovery, special-purpose vehicles and protocol development companies.

Some of the companies the fund has invested in and advised are MindMed MNMD, Cybin CYBN, Awakn Life Sciences AWKNF, atai Life Sciences ATAI, Gilgamesh Therapeutics, Psilera, Tabula Rasa Ventures, Fluence, Wesana, Lucid News, Double Blind, Maya Health, Firefly VR and Myco Systemics.

Dan Ahrens, Managing Director & COO at AdvisorShares

Dan Ahrens has over two decades of experience in the financial services industry at the senior level in portfolio management, sales, finance, operations and compliance. 

Before serving as a portfolio manager at AdvisorShares, Ahrens founded SEC-registered investment advisor Ahrens Advisors, L.P. where he was portfolio manager of the Ladenburg Thalmann Gaming and Casino Fund, and was also president of the funds where he launched the Vice Fund (VICEX) and served as its original portfolio manager. 

AdvisorShares offers a series of actively managed, thematic ETFs that seek to provide concentrated equity to varying exposure to durable and innovative investment themes that can drive market trends and serve as complements or satellite equity holdings to a broad-based equity allocation.

The ETFs also provide diversification across accomplished portfolio managers and domestic and international investment strategies, holding varying investment approaches, styles and capitalizations.

Eager to get some advice from these experienced investors? Get your tickets to PCC now before prices go up.

Photo: Benzinga edit with photos by Twitter and LinkedIn.

Market News and Data brought to you by Benzinga APIs
Posted In: CannabisNewsPenny StocksPsychedelicsEventsMarketsAdvisorShares InvestmentsAndrew ChomerBenzinga Psychedelics Capital ConferenceCCCDan AhrensSimeon Schnapper
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

The Benzinga Cannabis Capital Conference is coming to Florida

The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.

Get your tickets now on – Prices will increase very soon!